How uneven diet and lifestyle may trigger IBD in adolescents and adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project maps quality of life and psychosexual health in young people with IBD (ages 18–35) and tests the effect of a Mediterranean-like 'Nordiet' on gut health and disease activity. The diet intervention uses natural, additive-free foods and outcomes include symptom scores, stool calprotectin, gut microbiota composition, and bacterial DNA in blood as markers of intestinal health. Physical activity, sleep, and autonomic balance are tracked using activity bracelets and heart rate variability to explore links between exercise, body composition, and disease activity. Psychosexual health and quality of life will also be measured by questionnaires and qualitative interviews to capture patient-reported outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* IBD, i.e., Mb Crohn or ulcerrative colitis
* Moderatively active disease (calprotectin 200-600)

Exclusion Criteria:

* Proctitis alone
* Inactive disease
* Severe flare up requiring in-patient care
* Planned change of treatment
* Antibiotic treatment during the last month
* Pregnancy
* Inability to understand Swedish
* Multimorbidity

Where it's running

• Skåne University Hospital
  Malmö, Sweden Recruiting

Study contacts

• Study coordinator: Klas Sjöberg, Adj professor
• Email: klas.sjoberg@med.lu.se
• Phone: +46 40 33 61 61

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MGT-006 safety and dosing study for ulcerative colitis

  This study tests an oral microbiome capsule called MGT-006 to see if it is safe and tolerable in adults with moderately active ulcerative colitis, and whether the gut bacteria engraft after treatment.

  Recruiting at 9 sites Phase 1/2 Metagen Therapeutics, Inc. · Naples, Florida and 11 other locations · NCT07913347

• PALI-2108 vs placebo for moderate to severe ulcerative colitis

  A phase 2 study to see if PALI-2108 helps people with moderate to severe ulcerative colitis more than a placebo.

  Recruiting at 28 sites Phase 2 Palisade Bio · Sun City, Arizona and 114 other locations · NCT07845487

• Nitazoxanide as an add-on therapy for mild-to-moderate ulcerative colitis

  A study tests whether adding nitazoxanide to standard UC treatment helps people with mild-to-moderate ulcerative colitis see more relief.

  Recruiting at 2 sites Phase 2/3 Tanta University · Tanta and 1 other locations · NCT07820046

• Fecal Transplants from Dai vs Han Donors for Ulcerative Colitis

  This study tests whether fecal microbiota transplantation from healthy Dai donors improves symptoms in adults with ulcerative colitis more than transplantation from healthy Han donors.

  Recruiting Phase 2 First Affiliated Hospital of Kunming Medical University · Kunming, Yunnan · NCT07814456

• Familial IBD Early Risk

  This study tests whether clinical, environmental, and immune factors in first-degree relatives of people with Crohn’s disease or ulcerative colitis can predict who will develop IBD.

  Recruiting Seattle Children's Hospital · Seattle, Washington · NCT07791862

• Probiotics and Trace Elements Added to Infliximab in Ulcerative Colitis

  This trial tests whether adding a Lactobacillus probiotic or trace elements to infliximab helps people with ulcerative colitis stay in remission.

  Recruiting Phase 4 National Hepatology & Tropical Medicine Research Institute · Cairo · NCT07758335

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.